Independent opinions of independent directors on 2021 profit distribution plan
In accordance with the Listing Rules of Shenzhen Stock Exchange, the governance standards of listed companies, the guiding opinions on the establishment of independent director system in listed companies, the articles of association, the independent director system and other relevant regulations and systems, as independent directors of Berry Genomics Co.Ltd(000710) (hereinafter referred to as “the company”), we hereby express the following independent opinions on the company’s profit distribution plan for 2021:
1. We believe that the company’s profit distribution plan for 2021 complies with the relevant provisions of the company law, the securities law and the notice on further implementing the matters related to cash dividends of listed companies, the guidelines for the supervision of listed companies No. 3 – cash dividends of listed companies, the articles of association and the arrangement for diluting current earnings per share and filling returns in major asset restructuring of the company.
2. Given that the company expects to expand its upstream and downstream business lines through investment and other means in the next 12 months and continue to improve its internal management structure (the company will timely submit relevant matters to the board of directors or the general meeting of shareholders for deliberation according to the importance level), the company plans not to distribute cash dividends, bonus shares or convert capital reserve into share capital in 2021.
We believe that the above profit distribution plan is in line with the actual situation of the company and does not damage the interests of minority shareholders.
3. We agree with the profit distribution plan for 2021 adopted at the 16th meeting of the ninth board of directors. The voting procedures of the board of directors are open and transparent, and the deliberation procedures comply with the relevant provisions of laws, regulations and the articles of association.
4. We agree to submit the above plan to the 2021 annual general meeting of shareholders of the company for deliberation.
Independent directors: Wang Xiuping, Li Guangchao, Wang Sijia April 14, 2022
